Cancer immunotherapy-induced endocrinopathies: Clinical behavior and therapeutic approach

被引：42

作者：

Iglesias, Pedro ^{[1
]}

机构：

[1] Hosp Ramon & Cajal, Dept Endocrinol, Ctra Colmenar,Km 9-100, E-28034 Madrid, Spain

来源：

EUROPEAN JOURNAL OF INTERNAL MEDICINE | 2018年 / 47卷

关键词：

Cancer; Immunotherapy; Endocrinopathies; Hypophysitis; Thyroiditis; Adrenalitis; Type; 1; diabetes; IPILIMUMAB; MELANOMA; BLOCKADE; ANTIBODIES; NIVOLUMAB; CTLA-4;

D O I：

10.1016/j.ejim.2017.08.019

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Cancer immunotherapy has proven to be effective in a wide variety of tumors. The use of immune checkpoint blocking monoclonal antibodies has become a standard treatment regimen in some of them as advanced melanoma. However, given the mechanism of action, its use may be associated with immune-related adverse events that may complicate the clinical course and prognosis of patients. Among these are autoimmune endocrine adverse effects, such as hypophysitis, hypo and hyperthyroidism, and adrenal insufficiency. This review focuses on the most relevant and new aspects related to the incidence, clinical presentation, diagnosis and treatment of these adverse effects associated with different types of immune checkpoint inhibitors in cancer immunotherapy. (c) 2017 European Federation of Internal Medicine. Published by Elsevier B.V. All rights reserved.

引用

页码：6 / 13

页数：8

共 93 条

[11] Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis [J].

Bertrand, Anne ;

Kostine, Marie ;

Barnetche, Thomas ;

Truchetet, Marie-Elise ;

Schaeverbeke, Thierry .

BMC MEDICINE, 2015, 13

[12] Cytotoxic T-Lymphocyte-associated antigen-4 blockage can induce autoimmune hypophysitis in patients with metastatic melanoma and renal cancer [J].

Blansfield, JA ;

Beck, KE ;

Tran, K ;

Yang, DC ;

Hughes, MS ;

Kammula, US ;

Royal, RE ;

Topalian, SL ;

Haworth, LR ;

Levy, C ;

Rosenberg, SA ;

Sherry, RM .

JOURNAL OF IMMUNOTHERAPY, 2005, 28 (06) :593-598

[13] Drug-Induced Graves Disease From CTLA-4 Receptor Suppression [J].

Borodic, Gary ;

Hinkle, David M. ;

Cia, Yihong .

OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY, 2011, 27 (04) :E87-E88

[14]

Brilli L, 2017, ENDOCRINE

[15] CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition [J].

Buchbinder, Elizabeth I. ;

Desai, Anupam .

AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2016, 39 (01) :98-106

[16] Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies [J].

Byun, David J. ;

Wolchok, Jedd D. ;

Rosenberg, Lynne M. ;

Girotra, Monica .

NATURE REVIEWS ENDOCRINOLOGY, 2017, 13 (04) :195-207

[17] Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study [J].

Calabro, Luana ;

Morra, Aldo ;

Fonsatti, Ester ;

Cutaia, Omella ;

Fazio, Carolina ;

Annesi, Diego ;

Lenoci, Marica ;

Amato, Giovanni ;

Danielli, Riccardo ;

Altomonte, Maresa ;

Giannarelli, Diana ;

Di Giacomo, Anna Maria ;

Maio, Michele .

LANCET RESPIRATORY MEDICINE, 2015, 3 (04) :301-309

[18] Ipilimumab-Induced Hypophysitis: MR Imaging Findings [J].

Carpenter, K. J. ;

Murtagh, R. D. ;

Lilienfeld, H. ;

Weber, J. ;

Murtagh, F. R. .

AMERICAN JOURNAL OF NEURORADIOLOGY, 2009, 30 (09) :1751-1753

[19] A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes [J].

Chae, Young Kwang ;

Chiec, Lauren ;

Mohindra, Nisha ;

Gentzler, Ryan ;

Patel, Jyoti ;

Giles, Francis .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2017, 66 (01) :25-32

[20] Ipilimumab treatment associated pituitary hypophysitis: Clinical presentation and imaging diagnosis [J].

Chodakiewitz, Yosef ;

Brown, Sanford ;

Boxerman, Jerrold L. ;

Brody, Jeffrey M. ;

Rogg, Jeffrey M. .

CLINICAL NEUROLOGY AND NEUROSURGERY, 2014, 125 :125-130

← 1 2 3 4 5 6 7 8 9 10 →